Diagnosis and Management of T2-High Asthma

Andrea M. Coverstone, Max A. Seibold, Michael C. Peters

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Abstract

Type 2 (T2) inflammation plays a key role in the pathogenesis of asthma. IL-4, IL-5, and IL-13, along with other inflammatory mediators, lead to increased cellular eosinophilic inflammation. It is likely that around half of all patients with asthma have evidence of T2-high inflammation. Sputum and blood eosinophils, exhaled nitric oxide, blood IgE levels, and airway gene expression markers are frequently used biomarkers of T2-high asthma. Individuals with T2-high asthma tend to have several features of increased asthma severity, including reduced lung function and increased rates of asthma exacerbations, and T2-high patients demonstrate distinct pathologic features including increased airway remodeling and alterations in airway mucus production. Several monoclonal antibodies are now available to treat individuals with T2-high asthma and these medications significantly reduce asthma exacerbation rates.

Original languageEnglish
Pages (from-to)442-450
Number of pages9
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume8
Issue number2
DOIs
StatePublished - Feb 2020

Keywords

  • Asthma
  • Biomarkers in asthma
  • Monoclonal antibody therapy
  • Type 2 inflammation

Fingerprint

Dive into the research topics of 'Diagnosis and Management of T2-High Asthma'. Together they form a unique fingerprint.

Cite this